This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

Glucocorticoid and glycolysis inhibitors cooperatively abrogate acute graft-versus-host disease

October 18th, 2022
Glucocorticoid and glycolysis inhibitors cooperatively abrogate acute graft-versus-host disease
Schematic illustration of T cell glycolysis in GvHD, and GCs and glycolysis inhibitors cooperatively abrogate aGvHD.MP, methylprednisolone, which is one of glucorticosteroids; 3PO, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one, which is a glycolysis inhibitor. Credit: ©Science China Press

This study was designed by Professor. Yuan Kong (Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease) and Professor. Xiao-Jun Huang (Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease). Although allogeneic haematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for hematopoietic disorders, aGvHD remains a major complication after allo-HSCT. GCs are the standard first-line therapy for acute graft-versus-host disease (aGvHD), but nearly 50% of aGvHD patients have no response to GCs. The role of T cell metabolism in murine aGvHD was recently reported. However, whether GCs and metabolism regulators could cooperatively suppress T cell alloreactivity and ameliorate aGvHD remains to be elucidated. In the current study, increased glycolysis, characterized by elevated 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), and higher rates of glucose consumption and lactate production were found in T cells from aGvHD patients. Genetic upregulation of PFKFB3 induced T cell proliferation and differentiation into proinflammatory cells. In a humanized mouse model, PFKFB3-overexpressing or PFKFB3-silenced T cells aggravated or prevented aGvHD, respectively. Importantly, their integrated data from patient samples in vitro, in a humanized xenogeneic murine model of aGvHD and graft-versus-leukaemia (GVL) demonstrate that GCs combined with a glycolysis inhibitor could cooperatively reduce the alloreactivity of T cells and ameliorate aGvHD without loss of GVL effects. Together, the current study indicated that glycolysis is critical for T cell activation and induction of human aGvHD. Therefore, the regulation of glycolysis offers a potential pathogenesis-oriented therapeutic strategy for aGvHD patients. GCs combined with glycolysis inhibitors promises to be a novel first-line combination therapy for aGvHD patients.

More information:
Qi Wen et al, Glucocorticoid and glycolysis inhibitors cooperatively abrogate acute graft-versus-host disease, Science China Life Sciences (2022). DOI: 10.1007/s11427-022-2170-2

Provided by Science China Press

Citation: Glucocorticoid and glycolysis inhibitors cooperatively abrogate acute graft-versus-host disease (2022, October 18) retrieved 31 October 2024 from https://sciencex.com/wire-news/427513562/glucocorticoid-and-glycolysis-inhibitors-cooperatively-abrogate.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
Back to list